HRP20160939T1 - Pripravci za liječenje neuroloških poremećaja - Google Patents

Pripravci za liječenje neuroloških poremećaja Download PDF

Info

Publication number
HRP20160939T1
HRP20160939T1 HRP20160939TT HRP20160939T HRP20160939T1 HR P20160939 T1 HRP20160939 T1 HR P20160939T1 HR P20160939T T HRP20160939T T HR P20160939TT HR P20160939 T HRP20160939 T HR P20160939T HR P20160939 T1 HRP20160939 T1 HR P20160939T1
Authority
HR
Croatia
Prior art keywords
preparation according
dose
acid
preparation
amount
Prior art date
Application number
HRP20160939TT
Other languages
English (en)
Croatian (hr)
Inventor
Marios Pantzaris
Ioannis Patrikios
Georgios LUOKAIDIS
Original Assignee
Palupa Medical Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46275907&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20160939(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Palupa Medical Ltd. filed Critical Palupa Medical Ltd.
Publication of HRP20160939T1 publication Critical patent/HRP20160939T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
HRP20160939TT 2011-03-29 2012-03-28 Pripravci za liječenje neuroloških poremećaja HRP20160939T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161469081P 2011-03-29 2011-03-29
EP12727411.6A EP2691086B1 (en) 2011-03-29 2012-03-28 Compositions for the treatment of neurologic disorders
PCT/IB2012/000824 WO2012131493A1 (en) 2011-03-29 2012-03-28 Compositions for the treatment of neurologic disorders

Publications (1)

Publication Number Publication Date
HRP20160939T1 true HRP20160939T1 (hr) 2016-10-07

Family

ID=46275907

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20160939TT HRP20160939T1 (hr) 2011-03-29 2012-03-28 Pripravci za liječenje neuroloških poremećaja

Country Status (20)

Country Link
US (2) US20120252888A1 (enExample)
EP (1) EP2691086B1 (enExample)
JP (1) JP6092843B2 (enExample)
CN (1) CN104010634B (enExample)
AU (1) AU2012235869B2 (enExample)
BR (1) BR112013025088B1 (enExample)
CA (1) CA2831506C (enExample)
CY (1) CY1117828T1 (enExample)
DK (1) DK2691086T3 (enExample)
EA (1) EA025232B1 (enExample)
ES (1) ES2585066T3 (enExample)
GE (1) GEP201606568B (enExample)
HR (1) HRP20160939T1 (enExample)
HU (1) HUE028065T2 (enExample)
IL (1) IL228541A (enExample)
MX (1) MX2013011295A (enExample)
PL (1) PL2691086T3 (enExample)
UA (1) UA114706C2 (enExample)
WO (1) WO2012131493A1 (enExample)
ZA (1) ZA201307256B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10709680B2 (en) * 2011-07-18 2020-07-14 Physicians Recommended Nutriceuticals, Llc Methods for treating dry eye
ITMI20130354A1 (it) 2013-03-08 2014-09-09 Again Life Italia Srl Miscela di acidi grassi (f.a.g. fatty acids group) per uso nel trattamento di patologie infiammatorie.
US20160279095A1 (en) * 2013-11-12 2016-09-29 Abbott Laboratories Use of nutritional compositions including natural vitamin e, and polyunsaturated fatty acid
TWI725937B (zh) * 2014-06-06 2021-05-01 美商海洋原料公司 ω-３組成物、劑型及使用方法
EP3277101A4 (en) * 2014-11-07 2019-01-16 Vadakkemuri, Mathew Jolly OPTIMIZED NUTRITION FATTY ACID COMPOSITION
DE102015109352A1 (de) * 2015-06-12 2016-12-15 K. D. Pharma Bexbach Gmbh Anwendung von Omega-3- und/oder Omega-6-Fettsäure(n)
AR102008A1 (es) * 2015-09-24 2017-01-25 Brix S R L Ingrediente farmacéutico activo (ifa) oleoso para el tratamiento de afecciones de la piel, composiciones que lo comprenden y su uso para prepararlas
WO2017213490A1 (en) 2016-06-10 2017-12-14 N.V. Nutricia Method for controlling neuroinflammation
EP3534884A1 (en) 2016-11-04 2019-09-11 Immd SP. Zo.o Intelligent delivery of ingested and absorbed molecules
CN109125311A (zh) * 2018-06-26 2019-01-04 东南大学 预防或治疗阿尔茨海默症的药物组合物及其应用
WO2022170232A1 (en) * 2021-02-08 2022-08-11 Synaptogenix, Inc. Treatment of multiple sclerosis using pkc activators
WO2022170226A1 (en) * 2021-02-08 2022-08-11 Synaptogenix, Inc. Treatment of optic nerve inflammation using pkc activators
WO2023018703A1 (en) * 2021-08-09 2023-02-16 Kentucky Equine Research, Inc. Compositions and methods for modulating equine fatty acid profiles
WO2026041813A1 (en) * 2024-08-23 2026-02-26 University Of Alberta A lipid emulsion for brain regeneration and optimizing brain development via parenteral or enteral administration

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601399D0 (en) * 1986-01-21 1986-02-26 Delta Iota Ltd Information transmission/processing
GB8601915D0 (en) * 1986-01-27 1986-03-05 Efamol Ltd Pharmaceutical compositions
GB8813766D0 (en) 1988-06-10 1988-07-13 Efamol Holdings Essential fatty acid compositions
GB9001121D0 (en) * 1990-01-18 1990-03-21 Efamol Holdings Efa compositions and therapy
PH31403A (en) * 1991-03-01 1998-10-29 Warner Lambert Co Therapeutic compositions to protect and recuscitate mammalian cells and methods for preparing same.
GB9111900D0 (en) * 1991-06-03 1991-07-24 Efamol Holdings Fatty acid compositions
JP3283274B2 (ja) * 1991-06-15 2002-05-20 サントリー株式会社 新規組成物
GB9506837D0 (en) * 1995-04-03 1995-05-24 Scotia Holdings Plc Triglycerides
DE19757414A1 (de) * 1997-12-23 1999-07-01 Nutricia Nv Fettmischung
US6048891A (en) * 1998-12-17 2000-04-11 Loma Linda University Medical Center Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of natriuretic disease
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
US6677321B1 (en) * 1999-12-09 2004-01-13 Bruce Levin Methods and compositions for treatment of inflammatory disease
US7045683B2 (en) 2001-05-04 2006-05-16 Abbott Laboratories Δ4-desaturase genes and uses thereof
US20020198177A1 (en) * 2001-05-30 2002-12-26 Horrobin David Frederick Coenzyme Q and EPA
DK1417211T3 (da) 2001-07-27 2007-10-08 Neptune Technologies & Bioress Naturlige phospholipider af marin oprindelse, der indeholder flavonoider og polyumættede phospholipider, og deres anvendelse
US20030144219A1 (en) * 2001-11-15 2003-07-31 Phinney Stephen Dodge Formulations and methods for treatment or amelioration of inflammatory conditions
US20050080109A1 (en) 2003-10-09 2005-04-14 Papas Andreas M. Gamma-tocopherol and gamma-tocotrienol therapy for multiple sclerosis
US9265745B2 (en) * 2005-12-21 2016-02-23 Brudy Technology S.L. Use of DHA, EPA or DHA-derived EPA for treating a pathology associated with cellular oxidative damage
US20090196862A1 (en) * 2008-01-22 2009-08-06 William Davis High dosage Vitamin D
JP2010155799A (ja) * 2008-12-26 2010-07-15 Fujifilm Corp 粉末組成物及びそれを含む食品
CN102438468B (zh) * 2009-04-17 2014-06-04 纳塔克制药有限公司 富含低含量植烷酸的ω-3脂肪酸的组合物

Also Published As

Publication number Publication date
NZ616554A (en) 2015-10-30
MX2013011295A (es) 2014-11-10
HK1194665A1 (zh) 2014-10-24
BR112013025088B1 (pt) 2021-12-14
DK2691086T3 (en) 2016-08-15
HUE028065T2 (en) 2016-11-28
ZA201307256B (en) 2014-12-23
CN104010634B (zh) 2017-06-09
UA114706C2 (uk) 2017-07-25
PL2691086T3 (pl) 2016-12-30
CY1117828T1 (el) 2017-05-17
BR112013025088A2 (pt) 2017-02-14
JP2014512351A (ja) 2014-05-22
CN104010634A (zh) 2014-08-27
AU2012235869A1 (en) 2013-10-17
ES2585066T3 (es) 2016-10-03
US20120252888A1 (en) 2012-10-04
WO2012131493A1 (en) 2012-10-04
US20190343774A1 (en) 2019-11-14
JP6092843B2 (ja) 2017-03-08
AU2012235869B2 (en) 2017-04-20
CA2831506C (en) 2019-07-09
GEP201606568B (en) 2016-11-10
EA201391407A1 (ru) 2014-03-31
EP2691086A1 (en) 2014-02-05
EP2691086B1 (en) 2016-04-27
IL228541A0 (en) 2013-12-31
IL228541A (en) 2017-11-30
CA2831506A1 (en) 2012-10-04
EA025232B1 (ru) 2016-12-30

Similar Documents

Publication Publication Date Title
JP2014512351A5 (enExample)
Singh et al. Microbial production of docosahexaenoic acid (DHA, C22: 6)
EP1296670B1 (en) Therapeutic combinations of fatty acids
Kaur et al. Essential fatty acids as functional components of foods-a review
US8563609B2 (en) Nitro fatty acids - neuroprotection and/or inhibition of cognitive decline
JP7190013B2 (ja) エイコサペンタエン酸アルキルエステルを含有する組成物及びその製造方法
JP6092843B2 (ja) 神経障害の治療用組成物
WO2005089744A3 (en) Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
DE568606T1 (de) Mikrobielle öle und ihre verwendungen
Auvin Fatty acid oxidation and epilepsy
EP2216318A3 (en) Resolvins: Biotemplates for therapeutic interventions
WO2006078457A3 (en) Use of resolvins to treat gastrointestinal diseases
DK1121115T4 (da) PUFA-tilskud
UA111967C2 (uk) Оздоровчий харчовий продукт, що містить етилові естери жирних кислот з лляної олії, і спосіб його одержання
UA89207C2 (ru) Применение длинноцепочечных полиненасыщенных жирных кислот для получения жидкой питательной смеси для кормления детей
JPH0788301B2 (ja) 記憶喪失の治療または予防用組成物
WO2001076568B1 (en) Use of 13-hode as a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia
JP2018532015A5 (enExample)
RU2010121715A (ru) Распадающаяся во рту композиция, содержащая полиненасыщенные жирные кислоты, не имеющая неприятного запаха или вкуса
JP2012508791A5 (enExample)
DE202013008190U1 (de) Zubereitung und deren Verwendung bei atopischer Dermatitis
Yurko-Mauro Memory improvement with docosahexaenoic acid Study (MIDAS)-brief review
Longhi Fatty Acids and the Brain Health
DE20103671U1 (de) Zusammensetzung umfassend L-Carnitin und mehrfach ungesättigte Fettsäuren
JP2017522278A5 (enExample)